Clinical trial
Safety of Insulin Detemir Produced by a New Process as Measured by Antibody…
NCT00447382 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT00447382 |
|---|---|
| Title | Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes |
| Official title | A 12-months Multi-national, Multi-centre, Double Blind, Randomised, Parallel Safety and Efficacy Comparison of Insulin Detemir Produced by the Current Process and Insulin Detemir Produced by the NN729 Process in Subjects With Type 1 Diabetes on a Basal-bolus Regimen With Insulin Aspart as the Bolus… |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes, Diabetes Mellitus, Type 1 |
| Intervention type | Drug |
| Interventions | insulin detemir, insulin aspart |
| Enrollment | 330 |
| Start date | Mar 1, 2007 |
| Primary completion | Jul 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Mar 14, 2007 |
| Last update posted | Jan 2, 2024 |
| Countries | Germany, North Macedonia, Russia, Serbia and Montenegro, South Africa |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: